Home Biosimilar Antibodies Immunology & Inflammation CD markers inhibitor Ubamatamab (Anti-CA125 & CD3)
For research use only. Not for use in humans.

Ubamatamab (Anti-CA125 & CD3)

Synonyms: REGN4018

Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa

Ubamatamab (Anti-CA125 & CD3)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 0
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa

Product Details

CAS No. 2305629-50-7
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.